Investigating the Utility of COVID-19 Antibody Testing in End-Stage Renal Disease Patients Receiving Haemodialysis: A Cohort Study in the United Kingdom

Olivia Wickens  
Salford Royal NHS Foundation Trust

Rajkumar Chinnadurai  
Salford Royal NHS Foundation Trust

Fahmida Mannan  
Salford Royal NHS Foundation Trust

Frida Svendsen  
Salford Royal NHS Foundation Trust

Mirza Y Baig  
Salford Royal NHS Foundation Trust

Chukwuma Chukwu  
Salford Royal NHS Foundation Trust

Ibrahim Ali  
Salford Royal NHS Foundation Trust

Christina Summersgill  
Salford Royal NHS Foundation Trust

Dawn Evans  
Salford Royal NHS Foundation Trust

Berckley V Antoine  
Salford Royal NHS Foundation Trust

Julie Oxton  
Salford Royal NHS Foundation Trust

Nathan Mairs  
Salford Royal NHS Foundation Trust

Emma Flanagan  
Salford Royal NHS Foundation Trust

Robert Oliver  
Salford Royal NHS Foundation Trust

Philip A Kalra  
Salford Royal NHS Foundation Trust
Dimitrios Poulakakos
Salford Royal NHS Foundation Trust

Research Article

Keywords: COVID-19, antibody testing, haemodialysis, end-stage renal disease

DOI: https://doi.org/10.21203/rs.3.rs-154513/v1

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

End-stage renal disease (ESRD) patients receiving haemodialysis (HD) are a vulnerable group of patients with increased mortality from COVID-19. Despite improved understanding, the duration of host immunity following COVID-19 infection and role of serological testing alone or in addition to real-time reverse transcription polymerase chain reaction (rRT-PCR) testing in the HD population is not fully understood, which this study aimed to investigate.

Methods

There were two parts to this study. Between 15\textsuperscript{th} March 2020 to 15\textsuperscript{th} July 2020, patients receiving HD who tested positive on rRT-PCR for SARS-CoV-2 were recruited into the COVID-19 arm, whilst PCR-negative patients were recruited to the epidemiological arm of the Salford Kidney Study (SKS). All patients underwent monthly testing for anti-SARS-CoV-2 antibodies as per routine clinical practice since August 2020. The aims were twofold: firstly, to determine seroprevalence and COVID-19 exposure in the epidemiological arm; secondly, to assess duration of the antibody response in the COVID-19 arm. Baseline characteristics were reviewed between groups. Statistical analysis was performed using SPSS. Mann-Whitney U and Chi-squared tests were used for testing significance of difference between groups.

Results

In our total HD population of 411 patients, 32 were PCR-positive for COVID-19. Of the remaining PCR-negative patients, 237 were recruited into the SKS study, of whom 12 (5.1\%) had detectable anti-SARS-CoV-2 antibodies. Of the 32 PCR-positive patients, 27 (84.4\%) were symptomatic, with 19 patients admitted to hospital due to their symptoms. A separate six patients were diagnosed with COVID-19 whilst as inpatient. Of the 22 patients in COVID-19 arm that underwent testing for anti-SARS-CoV-2 IgG antibodies beyond seven months, all had detectable antibodies.

A higher proportion of the PCR-positive patients were frail compared to PCR-negative patients (64.3\% vs 34.1\%, p=0.003). Other characteristics were similar between the groups. Over a median follow up of six months, a higher number of deaths were recorded in the PCR-positive group compared to the PCR-negative group (18.8\% vs 3.8\%, p<0.001).

Conclusions

Serological testing in the HD population is a valuable tool to determine seroprevalence, monitor exposure, and guide improvements for infection prevention and control (IPC) measures to help prevent local outbreaks. This study revealed HD patients mount a humoral response detectable until at least seven months after COVID-19 infection and provides hope of similar protection with the vaccines recently approved.
Background

Since the discovery of Coronavirus disease 2019 (COVID-19) in December 2019, caused by severe acute respiratory syndrome coronavirus-2 virus (SARS-CoV-2), we have witnessed a global pandemic. SARS-CoV-2 has become the seventh coronavirus to infect humans and the third identified coronavirus to cause a major outbreak in humans (1).

End-stage renal disease (ESRD) patients receiving haemodialysis (HD) have been identified as a particularly high-risk group of patients at increased risk of mortality from COVID-19 (2–4). This is because many dialysis patients have underlying chronic co-morbidities, are often of an older age group and have an impaired immune response. In addition, maintenance HD patients have significantly increased risk of exposure to SARS-CoV-2 as they are unable to self-isolate, having to attend frequent HD sessions, usually thrice per week, with associated risks during transport.

Molecular testing via respiratory tract swabs, analysed by real-time reverse transcription polymerase chain reaction (rRT-PCR), remains the gold-standard diagnostic test for suspected COVID-19. However, false-negatives can occur with an insufficient sample quantity of viral genome, improper sampling or missing the window period of viral replication (5). More recent tests involve viral antigen detection usually from nasopharyngeal (NP) swabs, which can provide results within 15 minutes (6). Both viral nucleic acid and viral antigen tests only test for the presence of active infection and have no role in the identification of past infection, although they have been reported to continue to remain positive due to prolonged viral shedding for up to 63 days following the onset of symptoms (7, 8). With high numbers of asymptomatic and pre-symptomatic cases or viral shedding post-infection, keeping infection transmission under control continues to remain an enormous challenge.

With the limitations of molecular testing for COVID-19, there has been much interest in the use of serological anti-SARS-CoV-2 antibody testing. With a broad spectrum of clinical presentation of COVID-19 from asymptomatic infection, or mild flu-like symptoms through to acute respiratory distress syndrome (ARDS), multi-organ failure and death, serological testing plays an important role in surveillance, epidemiological studies and as an indirect marker of infection. Serological testing can be used to monitor disease prevalence and evaluate screening measures and protocols aiming at limiting transmission within dialysis units. Additionally, serological testing is also essential to quantify the level and duration of antibody response after COVID-19 infection, as with loss of detectable anti-SARS-CoV-2 antibodies and short-lived humoral immunity there may be a risk of potential re-infection or viral reactivation, particularly whilst patients are awaiting vaccination (9). This is of particular concern in the vulnerable category of ESRD patients receiving maintenance HD, which are a high-risk group of patients at increased morbidity and mortality from infection with SARS-CoV-2 due to their impaired immune responses to infection and vaccination (10).

To this end, this study aimed at determining the seroprevalence of COVID-19 infection in our HD population. Additionally, serological testing was used to assess the duration of antibody response and immunity in those infected with COVID-19. Baseline characteristics were compared between patients who
Methods

Between 15th March 2020 to 15th July 2020, patients receiving HD who tested positive on rRT-PCR for SARS-CoV-2 were recruited into the COVID-19 arm, whilst the remainder of patients who tested negative for SARS-CoV-2 on rRT-PCR were recruited to the epidemiological arm of Salford Kidney Study (SKS). SKS is a prospective observational study in the United Kingdom which has recruited chronic kidney disease patients since the year 2002. The ethical approval of SKS has been extended to include dialysis patients (both HD and peritoneal dialysis (PD)) since 2016. This research work has been performed in accordance with the Declaration of Helsinki and SKS has ethical approval obtained from the North West - Greater Manchester South Research Ethics Committee, UK (reference number: 15/NW/0818). All 269 patients involved in our observational analysis have signed an informed consent.

Details of patients recruited into SKS are elaborated in the Research Registry (https://www.researchregistry.com; researchregistry5962). In brief, this is longitudinal epidemiological study that involves annual blood sampling with samples processed and stored at -75°C for subsequent research analysis (EDTA whole blood, serum, plasma, and citrate plasma). All adult patients who have provided informed consent are recruited to the SKS.

The protocol was amended to include a sub-study for COVID-19 positive patients in order to investigate the time course of development of antibodies and the longevity of antibody response in HD patients. This sub-study included collection and storage of blood samples at recruitment (at or shortly after COVID-19 infection) and at intervals of 8 to 14 days on five occasions after infection, followed by six monthly interval samples. From August 2020 onwards, every HD patient had COVID-19 IgG antibody testing at monthly intervals as per newly implemented routine clinical practice.

Serological testing

All sera collected for the initial antibody testing (May 2020) were measured via a CE marked chemiluminescent immunoassay (SNIBE, Shenzhen, China) and the analysis was performed by Medical Diagnostics Ltd. in conjunction with Affinity Biomarker Labs (11). Subsequent antibody tests were performed from 12th June 2020 via the Siemens’ immunoassay using acridinium ester chemiluminescent technology (12) which was introduced and performed in the hospital laboratory.

rRT-PCR testing

Initial rRT-PCR testing was performed if a patient was suspected to have COVID-19 or was contact case of a person with confirmed COVID-19. A suspected case was defined as a person exhibiting symptoms and signs based on Public Health England (PHE) criteria on screening prior to HD (or self-presentation). A contact case was defined as a person who received HD during the same or subsequent shift (possible
contact in waiting area) if there were greater than two positive cases in one shift. These patients would be transferred directly to the main base dialysis unit (Salford Royal Hospital) for testing and assessment and for their next dialysis sessions. If the initial rRT-PCR was negative for SARS-CoV-2 it was repeated at their following HD session, and if negative again and asymptomatic, they would return to their satellite unit. COVID-19 identification was performed via an upper respiratory tract swab for SARS-CoV2 by rRT-PCR.

**Data collection**

Data was collected at study baseline (rRT-PCR date between March and July 2020) from the electronic patient records. This included, demographics, body mass index (BMI), clinical frailty score (CFS) and comorbidities including history of diabetes and cardiovascular events. Blood results including full blood count, ferritin, and albumin were recorded at baseline or within two weeks from the monthly dialysis bloods for all available patients. All patients were followed up from study baseline to endpoints which included death, loss to follow up or an arbitrary study end date of 30\(^\text{th}\) October 2020. Serological testing for the 32 COVID-19 positive patients was recorded until 31\(^\text{st}\) December 2020.

**Study definitions**

A smoking history was defined as a patient reported history of smoking, irrespective of the number of cigarettes smoked. Cardiovascular disease (CVD) history included a composite of non-fatal cardiac arrest, acute coronary syndrome, myocardial infarction, peripheral vascular disease, cerebrovascular accident and congestive cardiac failure. Renin-angiotensin system inhibitors (RASI) medications included angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Frailty status was determined using the CFS, with any patient with a score of five and above on the CFS was defined as being frail (13,14).

**Statistics**

Statistical analysis was performed using SPSS version-23, licenced to the University of Manchester. Throughout the analysis, categorical values were expressed as number (%), and the p-value was derived using the Chi-square test. As most of the continuous values were non-normally distributed, they were expressed as median (interquartile range) and the Mann-Whitney U test was used to calculate the p-value. A p-value <0.05 was considered statistically significant in this study (15).

**Results**

**Seroprevalence of COVID-19 in asymptomatic PCR-negative HD population**

A total of 237 HD patients who were PCR-negative for COVID-19 consented out of a total HD population of 411, were recruited to the epidemiological arm of SKS. In this group of 237 patients, the first antibody was tested at a median of 62 days (interquartile range (IQR) 47-77) from the negative PCR test result. All
237 patients had the initial PCR test between April and July 2020. The seroprevalence of IgG to SARS-CoV-2 was 5.1% (n=12) in this group (Table 1).

**Serological testing in COVID-19 PCR-positive patients**

A total of 32 patients receiving HD who tested positive for SARS-CoV-2 were recruited into COVID-19 arm of the SKS. 27 patients (84.4%) were symptomatic for COVID-19 of which, 19 patients (59.4%) were admitted to hospital due to their symptoms and a separate six patients (18.8%) were diagnosed with COVID-19 whilst an inpatient. The first antibody was tested at a median of 94 days (IQR 84-99) from the positive PCR test result and 96.9% (n = 31) had detectable IgG to SARS-CoV-2. Sera for COVID-19 antibodies were collected at regular time points, up to 6 times (median number of days prior to obtaining second, third, fourth, fifth and sixth samples were 120, 152, 185, 215 and 242 respectively) as seen on Table 2.

Of the 32 patients, one patient had undetectable antibodies from the second antibody test onwards. Another patient had undetectable antibodies from the second antibody until the sixth antibody test in which antibodies were then detected, which is the reason for the reduced percentage of patients with detectable antibodies at some of the sampling time points. In the sixth antibody collection point all the patients (n=22) had detectable antibodies with the one patient who had undetectable antibodies from the second test onwards not having testing at this timepoint. There was also one patient who had undetectable antibodies on the initial antibody test who then was found to have positive antibodies on all subsequent testing. The number of COVID-19 PCR-positive patients who had more than one serum antibody level taken fluctuated over time (n= 21; n =18; n=20, n=17, n=22 at second, third, fourth, fifth and sixth antibody samples respectively). The decline in patient numbers from baseline were due to death (n = 6), dialysis independence (n = 2) and not all samples were retrieved at the scheduled time points due to practical challenges related to the pandemic (transfer of patients between unit and impact of the pandemic on research capacity).

Of the 22 PCR-positive patients that were revealed to have detectable antibodies at a median of 242 days (IQR 233-250) from PCR positivity, 13 were admitted to hospital and three acquired COVID-19 infection whilst an inpatient. Of these 22 patients, 17 were symptomatic with COVID-19. Although the number of patients with detectable IgG antibodies to SARS-CoV2 varied over the course of the study, seropositivity remained at least 88.2% or above at each sampling point.

**Comparison of baseline characteristics of COVID-19 PCR-negative and PCR-positive patients**

The baseline characteristics for the study population are presented as a comparison between these two groups in Table 3. The median age of the study population was 61 years (IQR 50-73) and a predominance of males and Caucasian ethnicity, though not significantly different between the groups. The groups were similar in the baseline clinical characteristics including smoking history, BMI, history of diabetes and cardiovascular diseases apart from the proportion of patients in the COVID-19 positive group were more clinically frail (64.3% vs 34.1%; p=0.003). Over a median follow up of 5.6 months, a higher proportion of deaths was observed in the COVID-19 positive group (18.8% vs 3.8%; p<0.001), although 10 patients in
the rRT-PCR negative group tested positive in the follow-up period. Moreover, the COVID-19 positive group also had a higher rate of COVID-19 related hospital admissions than that recorded in the PCR-negative group (59.4% vs 1.3%; p<0.001).

**Discussion**

Our study has revealed a seroprevalence of 5.1% in the maintenance, asymptomatic HD population. In the 22 of the 32 COVID-19 PCR-positive patients who had antibodies tested beyond seven months, 100% still had detectable anti-SARS-CoV2 antibodies. The majority of baseline characteristics were similar between both COVID-19 PCR-negative and positive patients, although there was a statistically higher prevalence of frailty in the PCR-positive group.

Patients with ESRD receiving HD, in particular in-centre dialysis patients, have a higher chance of acquiring COVID-19 infection due to their regular contacts with health care personals and other people when they attend for their dialysis sessions. They are a vulnerable group of patients who are at risk of severe COVID-19 disease due to their comorbidities and frailty (2, 16). Serological testing is key in monitoring seroprevalence in this high-risk category of patients, enabling continuing review and monitoring of current IPC measures. A previous serosurvey from 316 healthcare workers in a tertiary centre in the North West England demonstrated a higher seroprevalence in healthcare workers directly involved in patient care (DIPC), demonstrating enhanced personal protective equipment (PPE) were justified for DIPC healthcare workers in renal services (17). Our results revealed a slightly lower seroprevalence compared to the seroprevalence of 6.4% in healthy adult blood donors within the North West of the UK in the same period (18). The lower seroprevalence is likely explained by the introduction of enhanced IPC measures and guidance resulting in reduced local transmission and outbreaks (19–21).

Due to the recent discovery of SARS-CoV-2, knowledge and understanding of the time host antibodies remain detectable and the immunological response to infection is limited. Out of the 32 PCR-positive patients, one patient had undetectable antibodies 112 days after the PCR result on the first antibody test performed via CE marked chemiluminescent immunoassay. It was not until 132 days after the positive PCR that anti-SARS-CoV-2 antibodies were detected in this patient via the Siemens’ immunoassay. This may have been explained by the different assays used or that the initial test may have been a false negative. In all subsequent antibody tests for this patient there were detectable antibodies.

A second patient had detectable antibodies on the first and sixth antibody testing points, with undetectable antibodies in between these timepoints, of which the reason for this inconsistency is unclear. All antibody tests for this patient except for the initial test were analysed via the Siemans’ assay. Of importance, the rRT-PCR testing in between the first and sixth antibody testing for this patient were negative and therefore unlikely to have been caused by reinfection.

A third patient had undetectable antibodies from the second antibody test onwards. The duration between the positive PCR test and positive antibody test for this patient was 109 days revealing a good initial duration of host antibody response.
It is thought that the degree of natural immunity an individual develops might be associated with severity of infection, with reports of higher antibody titres to SARS-CoV-2 in patients with a more severe clinical course of infection (22, 23). The patient that had undetectable antibodies from the second antibody test onwards was not admitted to hospital and one possible explanation may have been that they experienced a milder clinical course of infection and subsequently a lower titre and short-lived antibody response.

A total of 22 PCR-positive patients were revealed to have detectable antibodies at a median of 242 days (IQR 233–250) from PCR positivity. The results are very encouraging in that 100% of these 22 patients who underwent serological testing at greater than seven months after initial infection had anti-SARS-CoV-2 antibodies detectable. This finding indicates that ESRD patients receiving HD are able to mount a good immune response to COVID-19. Of importance patients may still have cellular immunity even when antibody testing for serological immunity is undetectable.

The limitations of the study include the use of different assays used between the first and second antibody tests, and the decline in the number of COVID-19 positive patients who underwent antibody testing with time. Additionally, antibody titres were unavailable to evaluate the change in levels over time. Furthermore, there may have been a possible volunteer bias for the epidemiologic part of the study with those consented having increased adherence to PHE guidance and IPC measures. Despite these limitations this is the first study to investigate the serial COVID-19 antibody status in HD patient over a period of at least seven months from initial infection, with the longest duration in one patient recorded up to 264 days from the initial PCR-positive swab.

Serological testing is easy to obtain from HD patients when they attend dialysis without the need for additional phlebotomy and this is an extremely valuable tool for determining seroprevalence and guiding IPC to reduce local transmission rates. It can be used to identify vulnerable patients in whom anti-SARS-CoV-2 antibodies are undetectable, whether due to lost immunity or absence of previous exposure to COVID-19, and who are potentially more susceptible to infection, be it an initial, recurrence or due to viral reactivation (9).

**Conclusions**

Ongoing surveillance of asymptomatic patients with the use of serological testing is essential in continuing to reduce the risk of transmission and outbreaks amongst dialysis units and ensuring safety standards are maintained. We report a lower regional seroprevalence during the period of this study probably due to effective PHE and departmental IPC measures.

Our data has revealed that the vast majority of high-risk ESRD patients receiving maintenance HD develop a good humoral response that in surviving patients is present beyond seven months after infection with COVID-19, providing hope of similar protection with vaccines now recently approved.
Abbreviations

CFS
clinical frailty score, CVD–cardiovascular disease, RASi - Renin-angiotensin system inhibitors, COVID-19 - Coronavirus disease 2019, ESRD - end-stage renal disease, HD–Haemodialysis, IPC - Infection prevention and control, IQR–interquartile range, NP–Nasopharyngeal, PD–peritoneal dialysis, PHE–Public Health England, RT-PCR - real-time reverse transcription polymerase chain reaction, SARS-CoV-2 - severe acute respiratory syndrome coronavirus-2 virus, SKS - Salford Kidney Study

Declarations

Ethics approval and consent to participate

This research work has been performed in accordance with the Declaration of Helsinki and Salford Kidney Study has ethical approval obtained from the North West - Greater Manchester South Research Ethics Committee, UK (reference number: 15/NW/0818). All 269 patients involved in our observational analysis have signed an informed consent.

Consent for publication

Not applicable

Availability of data and materials

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The analysis of the initial SARS-CoV-2 antibody testing was performed by Medical Diagnostics Ltd. in conjunction with Affinity biomarkers Labs free of charge. None of the authors has any other conflict of interest in relation to this manuscript.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Authors' contributions

1. Patient recruitment or data collation, or both- OW, FM, FS, YMB, CC, CS, DE, AVB, JO, NM, EF
2. Conception or design, or analysis and interpretation of data, or both- OW, RC, PK, DP
3. Drafting the article or revising it – OW, RC, PK, DP
4. Providing intellectual content of critical importance to the work described- OW, RC, IA, RO, PK, DP

5. Final approval of the version to be published- All authors.

Acknowledgements

The analysis of the initial SARS-CoV-2 antibody testing was performed by Medical Diagnostics Ltd. in conjunction with Affinity Biomarker Labs.

References

1. Liu YC, Kuo RL, Shih SR. COVID-19: The first documented coronavirus pandemic in history. Biomed J. 2020;43(4):328–333.

2. Goicoechea M, Cámara LA, Macías N, de Morales AM, Rojas ÁG, Bascuñana A et al. COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain. Kidney int. 2020 Jul 1;98(1):27–34.

3. Alberici F, Delbarba E, Manenti C, et al. A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection. Kidney Int. 2020;98(1):20–26.

4. Gansevoort RT, Hilbrands LB. CKD is a key risk factor for COVID-19 mortality. Nature Reviews Nephrology. 2020 Dec;16(12):705–6.

5. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020 Jul 28;71(15):778–785.

6. Augustine R, Das S, Hasan A, S A, Abdul Salam S, Augustine P et al. Rapid Antibody-Based COVID-19 Mass Surveillance: Relevance, Challenges, and Prospects in a Pandemic and Post-Pandemic World. J Clin Med. 2020;9(10):3372.

7. Widders A, Broom A and Broom J. SARS-CoV-2: The viral shedding vs infectivity dilemma. Infect Dis Health. 2020 Aug; 25(3): 210–215. Widders A, Broom A, Broom J. SARS-CoV-2: The viral shedding vs infectivity dilemma. Infect Dis Health. 2020 Aug;25(3):210–215.

8. Liu WD, Chang SY, Wang JT, et al. Prolonged virus shedding even after seroconversion in a patient with COVID-19. J Infect. 2020;81(2):318–356.

9. Gousseff M, Penot P, Gallay L, Batisse D, Benech N, Bouiller K et al. Clinical recurrences of COVID-19 symptoms after recovery: viral relapse, reinfection or inflammatory rebound?. J.Infect. 2020 Nov 1;81(5):816 – 46.

10. De Vriese AS, Reynders M. IgG Antibody Response to SARS-CoV-2 Infection and Viral RNA Persistence in Patients on Maintenance Hemodialysis. Am J Kidney Dis. 2020;76(3):440–441.

11. Padoan A, Cosma C, Sciacovelli L, Faggian D, Plebani M. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. Clin Chem Lab Med. 2020 Jun 25;58(7):1081–1088.
12. Evaluation of sensitivity and specificity of four commercially available SARS-CoV-2 antibody immunoassays. Public Health England. https://assets.publishing.service.gov.uk/Accessed 20 November 2020.

13. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A. global clinical measure of fitness and frailty in elderly people. CMAJ. 2005 Aug 30;173(5):489–95.

14. Hewitt J, Carter B, McCarthy K, Pearce L, Law J, Wilson F V. et al. Frailty predicts mortality in all emergency surgical admissions regardless of age. An observational study. Age Ageing. 2019;48(3):388–94.

15. Chinnadurai, R., Clarke, N.W. & Kalra, P.A. Associations of urological malignancies with renal progression and mortality in advanced chronic kidney disease: a propensity-matched cohort study. BMC Nephrol 21, 202 (2020).

16. Ng JH, Hirsch JS, Wanchoo R, Sachdeva M, Sakhiya V, Hong S et al. Outcomes of patients with end-stage kidney disease hospitalized with COVID-19. Kidney Int. 2020 Aug: 96 (6):1530–1539.

17. Poulakakos D, Sinha S, Kalra PA. SARS-CoV-2 antibody screening in healthcare workers in a tertiary centre in North West England. J Clin Virol. 2020; 129:104545.

18. Sero-surveillance of COVID-19. Public Health England. Updated 2 October 2020. https://www.gov.uk/government/publications/national-covid-19-surveillance-reports/sero-surveillance-of-covid-19. Accessed 28 December 2020.

19. National Institute for Health and Care Excellence (NICE) website. COVID-19 rapid guideline: dialysis service delivery. NICE guideline [NG160]. https://www.nice.org.uk/guidance/ng160. Accessed 28 December 2020.

20. Public Health England COVID-19: Guidance for the remobilisation of services within health and care settings. Infection prevention and control recommendations. Public Health England. August 20, 2020. https://assets.publishing.service.gov.uk/Accessed 28 December 2020.

21. Recommendations for Minimising the Risk of Transmission of SARS-CoV-2 (COVID-19) in UK Adult Haemodialysis Units. KQuIP COVID-19 HD Ensuring Patient Safety Work Stream. Version 3, 16th December 2020. https://renal.org/sites/renal.org/files/KQuIP/. Accessed 7 January 2021.

22. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020 Apr 29:1–4.

23. Xie J, Ding C, Li J, Wang Y, Guo H, Lu Z et al. Characteristics of patients with coronavirus disease (COVID-19) confirmed using an IgM-IgG antibody test. J Med Virol. 2020 Apr. doi:10.1002/jmv.25930.

Tables

Table 1 Antibody status and COVID-19 rRT-PCR positivity correlation at three months (first antibody)
| Variable | Total | COVID-19 PCR positive (32) | COVID-19 PCR negative (237) |
|----------|-------|---------------------------|-----------------------------|
|          | 269   | 43 (16%)                  | 12 (5.1%)                   |
| Number of patients with IgG antibody positive |       | 31 (96.9%)                |                             |
| Time between Covid-19 PCR and 1st antibody level, days | 62 (46-77) | 94 (84-99) | 59 (39-73) |

Categorical variables are expressed as number (%). Continuous variables are expressed as median (interquartile range).

rRT-PCR- real-time reverse transcription polymerase chain reaction

**Table 2 Trend of antibody status in the 32 positive patients**

| Variable | First antibody | Second antibody | Third antibody | Fourth antibody | Fifth antibody | Sixth antibody |
|----------|----------------|-----------------|----------------|-----------------|----------------|----------------|
| Number of patients with IgG antibody level available | 32 | 21 | 18 | 20 | 17 | 22 |
| Number of patients with IgG antibody level positive | 31(96.9%) | 19 (90.5%) | 17 (94.4%) | 18 (90%) | 15 (88.2%) | 22 (100%) |
| Median time between Covid-19 PCR and antibody, days | 94 (84-99) | 120 (109-124) | 152 (142-158) | 185 (174-189) | 215 (210-220) | 242 (233-250) |

Categorical variables are expressed as number (%). Continuous variables are expressed as median (interquartile range).

**Table 3 Baseline demographics of the recruited haemodialysis patients**
| Variable                          | Total patients (269) | COVID-19 PCR positive (32) | COVID-19 PCR negative (237) | p-value positive vs negative |
|----------------------------------|----------------------|-----------------------------|-----------------------------|-----------------------------|
| Age, years                       | 61 (50-73)           | 62 (54-75)                  | 60 (50-73)                  | 0.663                       |
| Gender, male                     | 177 (65.7%)          | 22 (68.7%)                  | 150 (63.3%)                 | 0.546                       |
| Ethnicity Caucasian              | 196 (72.8%)          | 25 (78%)                    | 171 (72.2%)                 | 0.476                       |
| Ethnicity BAME                   | 73 (27.2%)           | 7 (22%)                     | 66 (27.8%)                  |                             |
| Smoking history                  | 32 (11.9%)           | 8 (25%)                     | 24 (10.1%)                  | 0.344                       |
| Weight, Kg                       | 76 (64-89.5)         | 81.5 (63-95)                | 75 (65-89)                  | 0.405                       |
| BMI, Kg/m^2                      | 27 (23-31)           | 26.5 (22.5-32)              | 27 (24-31)                  | 0.939                       |
| Diabetes mellitus                | 97 (36.1%)           | 9 (28.1%)                   | 88 (37.1%)                  | 0.319                       |
| CVD                              | 60 (22.3%)           | 8 (25%)                     | 52 (21.9%)                  | 0.696                       |
| RASi                             | 93 (34.6%)           | 9 (28.1%)                   | 84 (35.4%)                  | 0.414                       |
| Frail (CFS >/=5), n=189          | 73/189 (38.6%)       | 18/28 (64.3%)               | 55/161 (34.1%)              | 0.003                       |
| Dialysis vintage, months         | 26 (11-64)           | 42 (14-71)                  | 25 (10-61)                  | 0.658                       |
| Dialysis access, AVF             | 167 (62.1%)          | 21 (65.5%)                  | 146 (61.6%)                 | 0.701                       |
| URR, %                           | 72 (65-78)           | 69 (66-77)                  | 73 (67-78)                  | 0.162                       |
| Albumin, g/L, n=262              | 37 (34-40)           | 38 (34-40)                  | 37 (34-40)                  | 0.873                       |
| Ferritin, ng/mL, n=262           | 367 (208-652)        | 364 (239-706)               | 368 (208-647)               | 0.761                       |
| TSats, %, n=262                  | 24 (16-34)           | 27 (17-36)                  | 24 (16-34)                  | 0.418                       |
| Vitamin D level, nmol/L, n=211   | 43 (28-55)           | 42 (24-53)                  | 37 (30-71)                  | 0.613                       |
| Haemoglobin, g/L, n=214          | 107 (96-117)         | 103 (86-120)                | 107 (96-117)                | 0.616                       |
| WCC, x10^9/L, n=214              | 7 (5-8)              | 6.6 (4-9)                   | 7 (5-8)                     | 0.925                       |
| Lymphocytes, x10^9/L, n=214      | 1.1 (0.7-1.45)       | 0.75 (0.5-1.2)              | 1.10 (0.8-1.5)              | 0.005                       |
| Outcomes                        | 204 (157-256) | 189 (117-262) | 207 (158-254) | 0.286 |
|--------------------------------|---------------|---------------|---------------|-------|
| Platelet count, x10^9/L, n=214 |               |               |               |       |
| Follow up, days                | 168 (145-183) | 197 (170-205) | 155 (145-179) | <0.001|
| COVID-19 related hospital admission | 28 (10.4%) | 19 (59.4%) | 3 (1.26%) | <0.001|
| ICU admission                  | 2             | 2             | 0             | -     |
| Deaths                         | 14 (5.6%)     | 6 (18.8%)     | 8 (3.8%)      | <0.001|

Categorical variables are expressed as number (%), and the p-value was derived using the Chi-square test. Continuous variables are expressed as median (interquartile range) and the Mann-Whitney U test was used to calculate the p-value.

BAME- black Asian minority ethnicity, BMI- body mass index, CVD-cardiovascular disease, RASi- renin-angiotensin system inhibitors, CFS-clinical frailty score, AVF- arterio-venous fistula, URR- urea reduction ratio, WCC- white cell count, TStats- transferrin saturations.